AMAG - AMAG Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5362.4M
Enterprise Value 3378.05M
Trailing P/E N/A
Forward P/E 1-5.84
PEG Ratio (5 yr expected) 10.10
Price/Sales (ttm)0.99
Price/Book (mrq)0.73
Enterprise Value/Revenue 31.04
Enterprise Value/EBITDA 6-6.82

Trading Information

Stock Price History

Beta (3Y Monthly) 0.28
52-Week Change 3-56.00%
S&P500 52-Week Change 31.52%
52 Week High 325.20
52 Week Low 36.81
50-Day Moving Average 39.62
200-Day Moving Average 311.45

Share Statistics

Avg Vol (3 month) 31.24M
Avg Vol (10 day) 32.17M
Shares Outstanding 533.77M
Float 15.81M
% Held by Insiders 12.05%
% Held by Institutions 1121.21%
Shares Short (Jul 31, 2019) 411.43M
Short Ratio (Jul 31, 2019) 415.02
Short % of Float (Jul 31, 2019) 454.49%
Short % of Shares Outstanding (Jul 31, 2019) 433.72%
Shares Short (prior month Jun 28, 2019) 410.57M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 22/3
Last Split Date 3Sep 26, 1991

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -64.33%
Operating Margin (ttm)-26.13%

Management Effectiveness

Return on Assets (ttm)-4.17%
Return on Equity (ttm)-53.54%

Income Statement

Revenue (ttm)364.27M
Revenue Per Share (ttm)10.61
Quarterly Revenue Growth (yoy)-46.60%
Gross Profit (ttm)230.21M
EBITDA -55.41M
Net Income Avi to Common (ttm)-328.33M
Diluted EPS (ttm)-6.83
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)261.04M
Total Cash Per Share (mrq)7.7
Total Debt (mrq)276.7M
Total Debt/Equity (mrq)55.39
Current Ratio (mrq)1.60
Book Value Per Share (mrq)14.73

Cash Flow Statement

Operating Cash Flow (ttm)-61.07M
Levered Free Cash Flow (ttm)72.5M